Alto Neuroscience Statistics
Total Valuation
ANRO has a market cap or net worth of $1.34 billion. The enterprise value is $1.12 billion.
| Market Cap | 1.34B |
| Enterprise Value | 1.12B |
Important Dates
The last earnings date was Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ANRO has 39.24 million shares outstanding. The number of shares has increased by 31.27% in one year.
| Current Share Class | 39.24M |
| Shares Outstanding | 39.24M |
| Shares Change (YoY) | +31.27% |
| Shares Change (QoQ) | +30.16% |
| Owned by Insiders (%) | 2.37% |
| Owned by Institutions (%) | 64.27% |
| Float | 29.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.58 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.85, with a Debt / Equity ratio of 0.11.
| Current Ratio | 14.85 |
| Quick Ratio | 14.64 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.04 |
Financial Efficiency
Return on equity (ROE) is -49.17% and return on invested capital (ROIC) is -28.06%.
| Return on Equity (ROE) | -49.17% |
| Return on Assets (ROA) | -26.79% |
| Return on Invested Capital (ROIC) | -28.06% |
| Return on Capital Employed (ROCE) | -37.18% |
| Weighted Average Cost of Capital (WACC) | 10.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.24M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +893.00% in the last 52 weeks. The beta is 1.09, so ANRO's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +893.00% |
| 50-Day Moving Average | 26.97 |
| 200-Day Moving Average | 20.96 |
| Relative Strength Index (RSI) | 71.28 |
| Average Volume (20 Days) | 420,080 |
Short Selling Information
The latest short interest is 3.24 million, so 8.24% of the outstanding shares have been sold short.
| Short Interest | 3.24M |
| Short Previous Month | 2.41M |
| Short % of Shares Out | 8.24% |
| Short % of Float | 10.91% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -88.27M |
| Pretax Income | -84.24M |
| Net Income | -84.24M |
| EBITDA | -87.58M |
| EBIT | -88.27M |
| Earnings Per Share (EPS) | -$2.38 |
Balance Sheet
The company has $243.73 million in cash and $23.29 million in debt, with a net cash position of $220.44 million or $5.62 per share.
| Cash & Cash Equivalents | 243.73M |
| Total Debt | 23.29M |
| Net Cash | 220.44M |
| Net Cash Per Share | $5.62 |
| Equity (Book Value) | 219.25M |
| Book Value Per Share | 6.25 |
| Working Capital | 230.67M |
Cash Flow
In the last 12 months, operating cash flow was -$68.29 million and capital expenditures -$556,000, giving a free cash flow of -$68.84 million.
| Operating Cash Flow | -68.29M |
| Capital Expenditures | -556,000 |
| Depreciation & Amortization | 689,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -68.84M |
| FCF Per Share | -$1.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.27% |
| Shareholder Yield | -31.27% |
| Earnings Yield | -6.33% |
| FCF Yield | -5.18% |
Analyst Forecast
The average price target for ANRO is $38.38, which is 12.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.38 |
| Price Target Difference | 12.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |